Physician profile
Stuart M Baird
NPI 1336383504
$3,309.18
in general payments reported to CMS, 2019-2025
14 companies · $333 in 2025
The $333 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $225 · 2021: $78.04 · 2022: $305 · 2023: $859 · 2024: $595 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,340.21 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $762.47 | 2019-2023 | Senza |
| Boston Scientific Corporation | $379.80 | 2019-2025 | General - Pain Management |
| Medtronic, INC. | $268.32 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Si-Bone, INC. | $148.87 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $129.42 | 2020-2023 | Ztlido |
| Spr Therapeutics, INC | $111.59 | 2024-2025 | Sprint Pns System |
| Forte Bio-Pharma LLC | $40.82 | 2023-2024 | Prolate, Nalocet |
| Nalu Medical, INC. | $36.55 | 2022-2024 | Nalu Neurostimulation System |
| Globus Medical, INC. | $20.16 | 2025 | Senza |
| Biotronik Nro, INC. | $19.21 | 2023 | Biotronik |
| Azurity Pharmaceuticals, INC. | $19.02 | 2023 | Horizant |
| Assertio Therapeutics, INC. | $17.13 | 2019 | |
| Saluda Medical Americas, INC. | $15.61 | 2023 | Evoke Scs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.